AzTrials
AzTrials

AmnesiaNCT02796287

Longitudinal Monitoring of Cerebral Connectivity 3T MRI in Patients With a Transcient Global Amnesia

A study testing achieving a neuropsychological examination in the acute amnesic phase, Neurological consultation with neuropsychological evaluation and MRI in people with Amnesia, run by Fondation Hôpital Saint-Joseph at 1 site in France.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The transient global amnesia (IA) is defined clinically as a temporary suspension and isolated from the ante and retrograde memory, totally regressing within 24 hours. The causes of AI remain unknown. The diagnosis of IA is based on consensus clinical criteria including the absence of associated location marks. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Amnesia
What is being tested?
achieving a neuropsychological examination in the acute amnesic phase, Neurological consultation with neuropsychological evaluation and MRI
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1 participants
Where
1 siteFrance
Study dates
2 Sep 2015to 31 Dec 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with a typical transient global amnesia
  • Sent for MRI as part of usual care protocol

Who cannot join

  • Any contraindication of MRI
  • Atypical clinical and / or radiological
  • Other active disease of the Central Nervous System
  • Patients with a history of cerebral infarction

Trial locations and contacts

1 site in 1 country.

France1 site
  • Groupe Hopitalier Paris Saint Joseph Service de radiologie

    Paris, Île-de-France Region, 75014

Other trials in France

About this study

The transient global amnesia (IA) is defined clinically as a temporary suspension and isolated from the ante and retrograde memory, totally regressing within 24 hours. The causes of AI remain unknown. The diagnosis of IA is based on consensus clinical criteria including the absence of associated location marks. In clinical practice, the MRI is often performed in conjunction with clinical examination because it ensures the absence of differential diagnoses, including stroke.

The visualization of MRI signal abnormalities related to AI directly dependent on the completion time of the review in relation to the onset of symptoms. Typically, no signal abnormality is visible in the hyperacute phase (ie D0-D1) while punctate appear hyperintense on diffusion sequences in hippocampal structures from J2 to J7 to disappear completely. It has been previously demonstrated that the use of higher values of b and / or a better spatial resolution significantly increases the sensitivity of the broadcasting sequence for the detection of these abnormalities hippocampal signal. At St. Joseph Hospital, Investigators explore the AI suspected patients with diffusion tensor sequence (DTI) on our high resolution 3T MRI.

Compared to the classical diffusion sequence, DTI is characterized by the use of a greater number of directions in which the diffusion gradients are applied. One advantage of this technique is to be able to perform tractography of white matter fibers. Thus the "connectome" is a new technique for post-processing of DTI images based tractography and to assess all the networks of nerve fibers in the brain. By this technique, the values of average diffusivity (MD) and fractional anisotropy (FA) can be measured along each of the studied nerve fibers. Group studies thus become feasible to compare quantitatively healthy subjects and patients groups in terms of structural differences within the connectome. The contribution of this technique was recently highlighted in patients with temporal lobe epilepsy.

Read the detailed description
  1. / OBJECTIVES The main objective of our study is, using the DTI realized 3T to: 1.1 Main Objective
  • Highlight changes in brain connectivity induced by the occurrence of transient global amnesia in acute and monitor these remote anomalies (up to 1 year after the initial episode IA). 1.2 Secondary Objectives
  • Correlate brain connectivity abnormalities identified data of neuropsychological examination
  • Correlate brain connectivity abnormalities identified o Brain morphological data (volumes of gray matter, white matter, hippocampal structures and LCS) o potential hippocampal hyperintensities visible in the acute phase of the diffusion images (number and laterality) 1.3 Methodology DESIGN: biomedical, prospective single-center on topics of AI episode as part of their medical care within the hospital group Paris Saint-Joseph, 185 Rue Raymond Losserand 75014 Paris. Study duration: 2 years from May 2015 in the rate of inclusion estimated to average 2-3 patients per month (ie inclusion period of one year: from May 2015 to May 2016 and last follow-up in May 2017 ). start and end dates: May 2015 to May 2017 Number of topics to include: This is an exploratory study, single center, on a rare disease, the incidence of stroke is estimated amnesia of 3 to 8 patients per 100 000 per year according to recent studies.
  • Based on a feasibility study previously carried out within the department, Investigators estimate that approximately 30% from refusal to participate in the study.
  • Only 3T MRI allows for the proper sequences: it is only available every other day to practice brain MRI In this context, Investigators therefore believe about 45 the number of subjects may be recruited during the period of inclusion (2 years)
  1. / COURSE OF STUDY 2.1 Patients and MRI Only patients referred for achieving their brain MRI as part of a typical transient global amnesia in the Radiology Department of the Paris Saint Joseph Hospital Group will be included in succession. For each subject, the following clinical data will be collected:
  • Age, sex
  • Medical background
  • Duration of AI, date and circumstances of occurrence
  • Current Treatments In the acute phase, there is no change in the usual care of the patient. The patient has a consultation with a neurologist at D0 / D1 which ensures the typical character of the clinical presentation. An MRI is performed on day 2 of the onset of symptoms to confirm the diagnosis. The usual course of MRI is not modified in any way, it includes the reception of the patient, information on the MRI scan and search against-indications. The images are acquired using a 3T MRI (GE Discovery MR 750) with 32 elements antenna head. The conventional imaging protocol includes the DTI sequences, FLAIR and 3DT1 without gadolinium (or 15 minutes of acquisition). As part of the study, it is not directed modification of the imaging protocol. Changes in the management of patients related to the application of this protocol are:
  • To carry out a neuropsychological examination in the acute phase
  • Renew for one year the episode AI
  • neurological consultation with neuropsychological evaluation
  • brain MRI with the same protocol or an acquisition time of 15 minutes without gadolinium. Study design in Annex 2. 2.1 Post processing The post processing of the data will be conducted at the research platform of the Lille University Hospital, which specializes in advanced imaging techniques (Prof. Xavier Leclerc, Mr Renaud Lopes), and include the following steps:
  • From 3D T1 sequence: the parcellation of the cortex regions of interest is necessary for the evaluation of connectome, volume measurements of SG, SB, LCS and seahorses using the software " Freesurfer "
  • From the DTI sequence: obtaining connectivity maps for each subject with measurement of MD and FA
  • Statistical comparison of different groups of subjects (patients vs controls J2 (healthy subjects) patients at 1 year vs controls, patients at Day 2 vs 1 year) and obtaining connectivity graphs showing the significant differences between these groups in terms of FA and MD. The controls (healthy subjects) are obtained from the database "1000 connectomes" available online.
  1. / IMAGE ANALYSIS

Image analysis is done in two stages.

  1. / interpretation "clinical" images, immediately with the aim to answer the following questions:
  • There is a stroke? another injury? whether the patient is excluded from the study
  • Vascular leukopathy according to the scale of Fazekas? stigmata of ischemic or hemorrhagic lesions?
  • Typical hippocampal hyperintensities AI? laterality and the number of injuries will be collected for each subject.
  1. / post processing of images (see above).

4 / STATISTICAL ANALYSIS

  • Descriptive analysis of results
  • Comparison of connectivity graphs representing the values of FA and MD among the three groups of subjects: normal subjects, patients explored D2, explored patients at 1 year
  • SG volume comparison, SB, LCS and seahorses among the three groups of subjects: normal subjects, patients explored D2, explored patients at 1 year
  • Search correlation between connectivity and anomalies o 1 / lateral abnormal hippocampal signal,
  • 2 / volumes measured from the sequence and 3DT1
  • 3 / abnormal neuropsychological examination 5 / ETHICS / REGULATORY:

This protocol presents no added risk to the patient. The initial MRI examination D2 is routinely performed as part of routine monitoring of patients with IA.

Changes in the management of patients related to the application of this protocol is to renew 1-year episode of AI:

  • Neurological consultation with neuropsychological evaluation
  • Brain MRI with the same protocol as for acute MRI performed an acquisition time of 15 minutes without gadolinium.

Data processing will be carried out within the research platform of the Lille University Hospital of anonymized way. Collaboration is already underway with this research center with several joint publications in the field of inflammatory and vascular diseases. The principal investigator (Dr. Hodel) exercises in both structures.

To start searching the CRC GHPSJ, as a promoter must submit a permit application to the competent authority (ANSM for biomedical research out health product).

In accordance with Article L.1123-6 of the Public Health Code, the research protocol must be submitted by the proponent to the Patient Protection Committee of choice (CPP Ile de France II). The opinion of the committee is notified to the competent authority by the developer before the start of the research.

When the protocol has a quality control of the data by a CRA representative promoter and enters the scope of the CNIL simplified procedure, the developer will ask the head of the computer file (investigator-coordinator research) to commit to compliance with the methodology of reference MR001 simplified.

The inclusion of patients will occur after the patient's information and collection of written consent; its information and consent will be traced in his file.

The patient's consent is sought:

  1. / for the use of data acquired in the acute phase for research purposes
  2. / to make a new MRI and a consultation of Neurology at 1 year of onset of symptoms
Conditions
Amnesia
Being tested
achieving a neuropsychological examination in the acute amnesic phase, Neurological consultation with neuropsychological evaluation, MRI
Keywords
Amnesia, transient global amnesia
Medical subject headings
Amnesia, Amnesia, Transient Global

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • achieving a neuropsychological examination in the acute amnesic phaseProcedure or surgery

    achieving a neuropsychological examination in the acute phase in addition to the normal protocole

  • Neurological consultation with neuropsychological evaluationProcedure or surgery

    Neurological consultation with neuropsychological evaluation one year after the acute amnesic phase

  • MRIRadiation

    Brain MRI with the same protocol or an acquisition time of 15 minutes without gadolinium, one year after the acute amesic phase

Study groups in NCT02796287
Study groupRoleWhat they receive
Patients with Ictus amnesicExperimentalPatients admitted in the hospital as part of their medical care with amnesic Ictus episode
Receives: Procedure: achieving a neuropsychological examination in the acute amnesic phase; Procedure: Neurological consultation with neuropsychological evaluation; Radiation: MRI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Assessment of change of connectivity graphs representative of the FA (fraction anisotropy) facts

    Comparison of connectivity graphs representing the FA values between the three groups of subjects : normal subjects , patients explored J2, explored patients at 1 year

    Measured: Day 2, 1 year

  2. Assessment of change of connectivity graphs representative of the MD (mean diffusivity) facts

    Comparison of connectivity graphs representing the MD values between the three groups of subjects : normal subjects , patients explored J2, explored patients at 1 year

    Measured: Day 2, 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Jun 2016 (estimated)
  2. Study start2 Sep 2015
  3. Primary completion31 Dec 2018
  4. Study completion31 Dec 2018

Why it stopped: The principal investigator decided to stop the study.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
1 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02796287
Sponsor's protocol ID
ICTUS
Status last verified
Aug 2018
First submitted
2 Jun 2016
Last updated
15 Feb 2019
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing achieving a neuropsychological examination in the acute amnesic phase, Neurological consultation with neuropsychological evaluation and MRI in people with Amnesia, run by Fondation Hôpital Saint-Joseph at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 15 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: The principal investigator decided to stop the study.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Assessment of change of connectivity graphs representative of the FA (fraction anisotropy) facts (time frame: Day 2, 1 year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in